Disease Areas:
OtherDevice Types:
Asma-1,4000 SeriesThe study examined glycemic outcomes in 45 adult patients with type 1 diabetes who were treated with Technosphere insulin inhalation powder plus insulin degludec for an overall period of 30 weeks. FEV1 was assessed at baseline, 17 weeks, and 30 weeks using a Vitalograph Asma-1 respiratory monitor.
